Pregabalin
- Generic Name
- Pregabalin
- Brand Names
- Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H17NO2
- CAS Number
- 148553-50-8
- Unique Ingredient Identifier
- 55JG375S6M
- Background
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels. Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release). It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.
- Indication
Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
- Associated Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
- Associated Therapies
- -
Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT02238717
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, CL, Netherlands
Pregabalin for Alcohol Dependence
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2020-04-07
- Target Recruit Count
- 100
- Registration Number
- NCT02205879
- Locations
- 🇷🇺
St.-Petersburg Bekhterev Reserach Psychoneurological Institute, St.-Petersburg, Russian Federation
Treatment of Pain Associated With Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1301
- Registration Number
- NCT02187471
Treatment of Pain Associated With Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1270
- Registration Number
- NCT02187159
Treatment of Pain Associated With Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1293
- Registration Number
- NCT02146430
Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 78
- Registration Number
- NCT02120703
- Locations
- 🇵🇰
The Aga Khan University Hospital, Karachi, Sind, Pakistan
Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02037165
- Locations
- 🇩🇪
1320.3.1 Boehringer Ingelheim Investigational Site, Dornach, Germany
Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia
- Conditions
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT02024568
- Locations
- 🇮🇱
Assaf HaRofeh Medical Center, Be'er Ya'akov (Zerifin), Israel
Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 5
- Registration Number
- NCT02020122
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Evaluation of Preoperative Use of Pregabalin on Postoperative Analgesia After Laparoscopic Colorectal Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Larissa University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01940224
- Locations
- 🇬🇷
University Hospital of Larissa, Larissa, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.